SCHEMBL6636591

SCHEMBL6636591

Oc1ccc(-c2cn3ccccc3c2-c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.50
KDM4E B2RXH2 7/20 0.49
ALDH1A1 P00352 7/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
MAPT P10636 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
GFER P55789 1/20 0.46
HPGD P15428 5/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
GAA P10253 4/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
BCL2L1 Q07817 2/20 0.45
MMP3 P08254 1/20 0.45
ABL1 P00519 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1435638 0.89 HRH3 (0.53) HRH3KDM4EALDH1A1NPC1RAB9A
Iodide SCHEMBL10843763 0.88 HRH3 (0.52) HRH3KDM4EALDH1A1NPC1RAB9A
SCHEMBL10001600 0.81 HRH3 (0.48) HRH3KDM4EALDH1A1NPC1RAB9A
SCHEMBL6641388 0.80 HRH3 (0.50) HRH3KDM4EALDH1A1NPC1RAB9A
SCHEMBL6641997 0.80 KDM4E (0.56) HRH3KDM4EALDH1A1NPC1RAB9A
SCHEMBL9888857 0.78 KDM4E (0.49) HRH3KDM4EALDH1A1NPC1RAB9A
SCHEMBL9888862 0.77 KDM4E (0.47) HRH3KDM4EALDH1A1NPC1RAB9A
SCHEMBL6636660 0.76 HRH3 (0.56) HRH3KDM4EALDH1A1NPC1RAB9A
SCHEMBL23596094 0.75 HRH3 (0.44) HRH3KDM4EALDH1A1NPC1RAB9A
SCHEMBL9599556 0.75 KDM4E (0.42) HRH3KDM4EALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268479-B1 PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS ORTHO MCNEIL PHARM INC (US) 2004-01-28 EP disclosed
EP-1268479-A1 PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS Ortho-McNeil Pharmaceutical, Inc. (US) 2003-01-02 EP disclosed
US-20010051632-A1 Phenyl-substituted indolizines and tetrahydroindolizines ORTHO MCNEIL PHARMACEUTICAL, INC. 2001-12-13 US disclosed
WO-2001074814-A1 PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051632-A1 Phenyl-substituted indolizines and tetrahydroindolizines TPH2, TPH1, IDO2 HRH3 406/4885KDM4E 1223/4885ALDH1A1 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.